Official answer. Flavia Watson is the singer on the Humira commercial “Not always where I need to be” released July 16, 2018.

As AbbVie moved away from promotional spend on its aging megablockbuster Humira at the same time Sanofi and Regeneron stepped up their TV campaigns for Dupixent in 2021, you might be forgiven for thinking AbbVie was content to no longer top the annual largest TV drug ad spending lists.

Adalimumab (Humira) and biosimilars: medicine used for inflammation - NHS.

Humira is the brand name of the original adalimumab medicine. There are now 5 newer versions of adalimumab, known by the brand names Amgevita, Hyrimoz, Idacio, Imraldi and Yuflyma. These newer medicines are biosimilars.

Humira, a biologic drug used to treat various autoimmune diseases, including rheumatoid arthritis and psoriasis, holds the distinction of being the top-selling biologic drug globally, generating annual sales exceeding USD 20 billion.

A significant factor in Humira's success has been the absence of biosimilar competition. This is partially related to Paragraph IV settlement agreements negotiated between AbbVie and adalimumab biosimilar manufacturers.

Humira is used to treat many inflammatory conditions in adults, such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, and a skin condition called hidradenitis suppurativa.

HUMIRA is a prescription medicine used to treat moderate to severe Crohn's disease (CD) in adults and children 6 years of age and older. HUMIRA is a prescription medicine used to treat moderate to severe Crohn's disease (CD) in adults and children 6 years of age and older.

The drug suppresses the immune system by blocking the activity of TNF. TNF is a protein produced naturally by the body's immune system. Some people with certain autoimmune diseases produce too much TNF. Humira is designed to stop tumor necrosis factor-α, or TNF, from attacking healthy cells.

Adalimumab, sold under the brand name Humira, was approved for use in the United States in 2002. Adalimumab, sold under the brand names Humira and Trudexa, was approved for use in the European Union in September 2003.

Meanwhile, the heavyweight tumor necrosis factor (TNF) blocker Humira, which had been the best-selling prescription medicine for most of the past decade, raked in $21.2 billion in 2022, securing the second spot among the 50 best-selling pharmaceuticals.

Until recently, Humira was the world's biggest-selling non-COVID prescription drug, hitting a record $21.2 billion in sales for 2022. Humira cost the U.S. government more than $2.9 billion in 2021, according to data from the agency that runs the Medicare and Medicaid health programs.